Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
US |
|
Stevanato Group SpA
NYSE:STVN
|
IT |
|
H
|
Hextar Capital Bhd
KLSE:HEXCAP
|
MY |
|
Directel Holdings Ltd
HKEX:8337
|
HK |
|
HWA AG
XETRA:H9W
|
DE |
|
Narmada Agrobase Ltd
NSE:NARMADA
|
IN |
|
A
|
Alcom Group Bhd
KLSE:ALCOM
|
MY |
|
W
|
WidePoint Corp
AMEX:WYY
|
US |
|
Jiangsu King's Luck Brewery Joint-Stock Co Ltd
SSE:603369
|
CN |
|
Puya Semiconductor Shanghai Co Ltd
SSE:688766
|
CN |
|
Alembic Pharmaceuticals Ltd
NSE:APLLTD
|
IN |
|
Zhen Ding Technology Holding Ltd
TWSE:4958
|
KY |
|
Grinm Advanced Materials Co Ltd
SSE:600206
|
CN |
|
Ningbo Exciton Technology Co Ltd
SZSE:300566
|
CN |
|
Quantafuel ASA
OSE:QFUEL
|
NO |
|
B
|
Bms Birlesik Metal Sanayi ve Ticaret AS
IST:BMSTL.E
|
TR |
|
Koc Holding AS
IST:KCHOL.E
|
TR |
|
R S Software (India) Ltd
NSE:RSSOFTWARE
|
IN |
|
Beijing Zhidemai Technology Co Ltd
SZSE:300785
|
CN |
|
J
|
Jiangxi Sunshine Dairy Co Ltd
SZSE:001318
|
CN |
|
G
|
Guangdong Huiyun Titanium Industry Co Ltd
SZSE:300891
|
CN |
|
K
|
KCC Engineering & Construction Co Ltd
KOSDAQ:021320
|
KR |
Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
Cash Position: Cyclacel ended June 2024 with $6 million in cash and cash equivalents, up from $3.4 million at the end of 2023.
Clinical Progress: The company's lead program, fadra (an oral CDK2/9 inhibitor), is advancing in Phase II trials, with initial clinical activity data expected in Q4 2024.
Proof-of-Concept Study: Enrollment is progressing well for the Phase II proof-of-concept study targeting patients with specific chromosomal abnormalities (CDKN2A/CDKN2B).
Cost Management: R&D expenses declined significantly, with total R&D for Q2 2024 at $2 million compared to $4.7 million last year.
Runway: Management estimates current cash will fund operations into Q4 2024.
Upcoming Catalysts: Interim data from approximately a dozen patients in the enriched cohort are expected by the end of 2024.
